Information Journal Paper
APA:
Copy. (2017). Phase 1/2, multicenter, nonrandomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 35(-), 0-0. SID. https://sid.ir/paper/759155/en
Vancouver:
Copy. Phase 1/2, multicenter, nonrandomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2017;35(-):0-0. Available from: https://sid.ir/paper/759155/en
IEEE:
Copy, “Phase 1/2, multicenter, nonrandomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer,” JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. -, pp. 0–0, 2017, [Online]. Available: https://sid.ir/paper/759155/en